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Recent developments in sequencing technologies have made it possible to uncover both rare and common genetic variants. Genome-
wide association studies (GWASs) can test for the effect of common variants, whereas sequence-based association studies can evaluate
the cumulative effect of both rare and common variants on disease risk. Many groupwise association tests, including burden tests and
variance-component tests, have been proposed for this purpose. Although such tests do not exclude common variants from their eval-
uation, they focus mostly on testing the effect of rare variants by upweighting rare-variant effects and downweighting common-variant
effects and can therefore lose substantial power when both rare and common genetic variants in a region influence trait susceptibility.
There is increasing evidence that the allelic spectrum of risk variants at a given locus might include novel, rare, low-frequency, and com-
mon genetic variants. Here, we introduce several sequence kernel association tests to evaluate the cumulative effect of rare and common
variants. The proposed tests are computationally efficient and are applicable to both binary and continuous traits. Furthermore, they can
readily combine GWAS and whole-exome-sequencing data on the same individuals, when available, and are also applicable to deep-
resequencing data of GWAS loci. We evaluate these tests on data simulated under comprehensive scenarios and show that compared
with the most commonly used tests, including the burden and variance-component tests, they can achieve substantial increases in
power. We next show applications to sequencing studies for Crohn disease and autism spectrum disorders. The proposed tests have
been incorporated into the software package SKAT.Introduction
The rapid development of sequencing technologies has led
to the launch of numerous sequencing studies for many
complex traits.1 In addition to discovery of common vari-
ants, usually defined as those having a population fre-
quency of 5% or higher, sequencing allows discovery of
low-frequency and rare variants as well. The relative contri-
bution of rare and common variants to disease risk is
unknown for many traits, but it is reasonable to assume
that a combination of rare and common variants influ-
ences the risk of many complex diseases. Recent studies
have shown that novel, rare, low-frequency, and common
variants can all be contributory variants at the same disease
locus.2–4
Over the past several years, genome-wide association
studies (GWASs) have led to the identification of many
common genetic variants associated with risk of diverse
complex traits.5 Although the variants identified so far
usually explain only a small to modest part of the esti-
mated heritability for a given trait, it has been shown for
several traits, including schizophrenia (MIM 181500),
bipolar disorder (MIM 125480), autism (MIM 209850),
and human height (MIM 606255), that many common
variants with small effects might cumulatively explain a
substantial proportion of the heritability.6–9
The main strategy employed by GWASs has been to eval-
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The Amsuch as the Cochran-Armitage test for trend.10 Such a
variant-by-variant analysis has been shown to be under-
powered for rare variants, and consequently, many group-
wise association tests have been proposed,11–23 including
burden and variance-component (e.g., SKAT) tests.22
Most groupwise association tests use a weighting scheme
that upweights the contribution of rare variants and down-
weights the contribution of common variants,12 and they
thereby mostly test for the effect of rare variants. However,
the relative influence of rare and common variants is not
known a priori for any disease-related gene, and such a
weighting scheme can lead to loss of power when common
variants in a region under investigation are also associated
with disease. Under commonly used simulation scenarios,
the genetic variance explained by common variants in a
small genetic region can be higher than that explained
by rare variants in the region (see Appendix A). Currently,
rare and common variants are tested separately with the
use of different testing strategies (as described above).
However, because the overall goal is to identify genes
that contain disease risk variants, be they rare or common,
it is desirable to test for the combined effect of rare and
common variants with a unified statistical test that allows
both rare and common variants to contribute fully to the
overall test statistic.
In this paper, we develop omnibus procedures to test for
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and rare variants in the context of sequencing data and
propose a separation threshold that depends on the sample
size. We then propose several tests for combining burden
and variance-component test statistics for rare and com-
mon variants. These tests are applicable to both binary
and continuous traits and population- and family-based
designs. We show applications to sequencing studies for
Crohn disease (MIM 266600) and autism spectrum disor-
ders (ASDs).
Currently, whole-genome sequencing is very expensive
for large-scale association studies. Instead, whole-exome
sequencing (WES) focuses on a gene’s protein-coding com-
ponents, which represent about 1% of the whole genome.
On the other hand, many variants identified in GWASs are
in noncoding regions, as might be expected from the prev-
alence of noncoding variants assayed in these studies.24
Indeed, according to the Illumina Gene Annotation files
of Human1Mduo and HumanOmni5-4 arrays, over 90%
of the variants on the array are in intronic or intergenic re-
gions and only 3% and 8% are located in coding and
exonic regions, respectively. Because many WES studies
are performed on individuals with existing GWAS data,
an important application of the proposed methods is in
combining GWAS data withWES data on the same individ-
uals. Another application is to the study of deep resequenc-
ing of GWAS loci, where rare, low-frequency, and common
contributory variants are expected to coexist.2Material and Methods
Definition of a Threshold to Partition Variants into
Rare and Common Variants
As we mentioned in the Introduction, most of the existing
sequence-based association tests use a weighting function (usually
depending on the variant frequency) that upweights the contribu-
tion of rare variants and correspondingly downweights the con-
tribution of common variants.12,22 Such a weighting scheme is
necessary if both rare and common variants are to be included
together in the study of rare-variant effects (otherwise, common
variants dominate). However, when common variants are impor-
tant for disease risk, such an approach is likely to lose power. A
different way to combine rare and common variants together is
to first partition variants into two separate groups—rare and
common—and then combine the results from association tests
with variants in the two groups, e.g., with the use of combined
multivariate collapsing (CMC).11 In CMC, rare variants (e.g., those
with aminor allele frequency [MAF]< 0.01) are collapsed together,
whereas each common variant forms a separate group. Results
from rare and common variants are then combined with the use
of a multivariate Hotelling’s T-Square statistic. Even though this
approach involves the ad hoc choice of a frequency cutoff, it has
the advantage of allowing both rare and common variants to
better contribute to the overall test for the effect in the region,
although a large number of degrees of freedom (df) are used for
common variants.
A commonly used approach in the literature is to use a fixed-
frequency threshold T, e.g., 0.01, to partition variants into rare
and common groups. Variants with a sample frequency less than842 The American Journal of Human Genetics 92, 841–853, June 6, 20.01 are treated as rare, those with a frequency between 0.01 and
0.05 are treated as low frequency, and the rest are considered
common. A different approach is to define the threshold as a func-
tion of the total sample size. Intuitively, a variant with frequency
0.01 is rare in a small data set of 500 individuals but is quite
common in a much larger data set with, say, 100,000 individuals.
One large sample theory threshold25 is to take
T ¼ 1ﬃﬃﬃﬃﬃﬃ
2n
p ;
where n is the number of individuals in the study. Specifically, if
one defines a variant as being common if it can be analyzed by it-
self with moment-based statistics (such as sample mean), then a
natural asymptotic threshold is 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
, which is proportional to
the SD of the sample mean. Note that this threshold only depends
on the total sample size. It is not an optimal separation cutoff,
given that such a cutoff would necessarily depend also on the
true disease model, which is unknown to us.
In this setting, variants with MAF% 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
are considered rare,
whereas variants with MAF R 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
are considered common.
When n ¼ 500, then T ¼ 0.031. When n ¼ 10,000, then T ¼
0.007. In the Results, we perform sensitivity analyses to investigate
how this threshold compares with commonly used thresholds,
such as 0.01 or 0.05, under several disease models.
Testing for the Overall Effect of Rare and Common
Variants
To test for the overall effect of rare and common variants, we
consider here several possible approaches that make use of the pre-
viously developed burden and variance-component (SKAT) tests
for rare and common variants.18,22 One simple approach is based
on Fisher’s method of combining the p values from the rare
and common variant tests. Alternative approaches are based on
combining the test statistics directly by using weighted-sum statis-
tics. We start with this latter family of tests and then describe
Fisher’s combination method.
Model and Notations
We assume that n subjects are sequenced in a region (e.g., a gene)
that has m variants: m1 rare variants and m2 common variants
(m ¼ m1 þ m2). Let X be the n 3 m genotype matrix. We consider
regression model
g½EðYiÞ ¼ a0 þ CiaþXib; (Equation 1)
where gð,Þ is a link function and can be set to be the identity func-
tionwhen traits are continuous or the logistic functionwhen traits
are dichotomous; a ¼ ða1;.;apÞ0 are regression coefficients for
the covariates, Ci ¼ ðCi1;.;CipÞ, that we want to adjust for.
Xi ¼ ðXi1;.;XimÞ is the vector of genotypes for the ith individual,
and Yi is its trait value. b ¼ ðb1;.;bmÞ0 are regression coefficients
for the m genetic variants. We assume that b is a random variable
with EðbjÞ ¼ 0, VarðbjÞ ¼ w2j t, and corrðbj;bkÞ ¼ r for different j
and k. For testing the null hypothesis of no genetic effects,
H0 : b ¼ 0;
the variance-component score statistic has been proposed as21,22
Q r ¼

Ycm00KrYcm0;
where
Kr ¼ XWRrWX0;013
Table 1. Sequence-Based Association Tests: Existing Tests and the
Proposed RC-SKAT Tests
Method Name Description
Burden B original burden test
SKAT S original SKAT test
CMC C combined multivariate collapsing test
SKAT-NW SNW original SKAT test with no variant weighting
Burden-C BC combined sum test with burden tests for rare and
common variants
SKAT-C SC combined sum test with SKAT tests for rare and
common variants
Burden-A BA adaptive sum test with burden tests for rare and
common variants (rare variants are projected
over the common variants)
SKAT-A SA adaptive sum test with SKAT tests for rare and
common variants (rare variants are projected
over the common variants)
Burden-F BF Fisher’s method with burden tests for rare and
common variants
SKAT-F SF Fisher’s method with SKAT tests for rare and
common variantsin which Rr ¼ ð1 rÞIþ r110 specifies an exchangeable correla-
tion matrix and W ¼ diagðw1;.;wmÞ is a diagonal weight matrix;
for a dichotomous trait, cm0 is a vector of estimated probabilities of
Y under the null model. Although this class of tests is more
general, we restrict attention to two commonly used tests, the
burden test (when r ¼ 1) and the SKAT test (when r ¼ 0). These
score statistics are easily computed and can be written simply as
SKAT : Q r¼0 ¼
Pm
j¼1
w2j
Pn
i¼1

Yi dmi;0Xij2and
Burden : Q r¼1 ¼
"Pm
j¼1
wj
Pn
i¼1

Yi dmi;0Xij
#2
:
A weighting scheme that upweights rare variants and down-
weights common variants has been proposed for testing for rare-
variant effects: wj ¼ Betaðbpj ;1;25Þ, where bpj is the MAF estimated
on the basis of all subjects for variant j. The null distribution of
Qr is approximated by a mixture of c
2
1 distributions. Davies’
method26 or moment matching can be employed for calculating
the p value.
Here, we propose several tests that explicitly separate rare and
common variants. Let X1 be the n 3 m1 genotype matrix of rare
variants and X2 be the n 3 m2 genotype matrix of common vari-
ants. First, we rewrite the regression model in Equation 1 as
g½EðYiÞ ¼ a0 þCiaþX1ib1 þX2ib2; (Equation 2)
where X1i is the genotype vector of rare variants and X2i is the
genotype vector of common variants for the ith individual.
b1 ¼ ðb11;.;b1m1 Þ0 and b2 ¼ ðb21;.;b2m2 Þ0 are coefficient vectors
for rare and common variants, respectively. The null hypothesis
of no genetic effects in the region corresponds to
H0 : b1 ¼ 0; b2 ¼ 0:
Combined Sum Test of Rare- and Common-Variant
Effects
In order to test for the joint effect of rare and common variants in a
region, we combine score test statistics for rare and common
variants as a weighted sum. Suppose that b1j is a random variable
with Eðb1jÞ ¼ 0, Varðb1jÞ ¼ w21jð1 fÞt, and corrðb1j; b1kÞ ¼ r1 for
different j and k. Similarly, we assume that b2j is a random variable
with Eðb2jÞ ¼ 0, Varðb2jÞ ¼ w22jft, and corrðb2j; b2kÞ ¼ r2. The null
hypothesis of b1 ¼ b2 ¼ 0 is equivalent to t ¼ 0. A score test statis-
tic with given ðf; r1; r2Þ is
Qf;r1 ;r2 ¼ ð1 fÞðY bm0Þ0K1;r1 ðY bm0Þ þ fðY bm0Þ0K2;r2 ðY bm0Þ
¼ ð1 fÞQrare þ fQcommon;
which is a weighted sum of rare- and common-variant test statis-
tics and has weight parameter f, where K1;r1 ¼ X1W1Rr1W1X01
and K2;r2 ¼ X2W2Rr2W2X02. A simple approach is to select f
such that the rare and common variants contribute equally to
the test statistics. In particular, we choose f ¼ SD½Qrare=
ðSD½Qrare þ SD½QcommonÞ so that ð1 fÞQrare and fQcommon have
the same variance. The two weight matrices for rare and common
variants are general and can accommodate a large family of
possible weights. In this paper, we use different weight functions
for rare and common variants. In particular, for rare variants we
use the same weights as proposed in the original SKAT tests, i.e.,
w1j ¼ Betaðbpj ;1;25Þ. However, for common variants, this weight-
ing scheme does not work because it assigns almost zero weight
to common variants (e.g., w ¼ 0.0004 for a MAF of 0.30 butThe Amw ¼ 7.28 for a MAF of 0.05). Instead, for common variants,
we use w2j ¼ Betaðbpj ;0:5;0:5Þ,12 which slowly decreases with
increasing MAF. For example, for MAF ¼ 0.05, w ¼ 1.46, for
MAF ¼ 0.10, w ¼ 1.06, for MAF ¼ 0.30, w ¼ 0.69, and for MAF ¼
0.5, w ¼ 0.64.
For a given f, the null distribution of Qf;r1 ;r2 is a mixture of
c21 distributions, and a p value can be obtained efficiently as
follows. Let ðl1;.; lmÞ denote the eigenvalues of the following
matrix,
ð1 fÞP1=2K1;r1P1=2 þ fP1=2K2;r2P1=2;
where P ¼ bV1  bV1 ~Cð~C0 bV1 ~CÞ1 ~C0 bV1 is an n 3 n matrix, ~C is
an n 3 (p þ 1) matrix equal to [1 C], and bV is a diagonal matrix
of the variance of Y under the null hypothesis. It has been shown
that Qf;r1 ;r2 follows a mixture of c
2
1 distributions,Xm
j¼1
ljc
2
1;j;
where c21;j are independent and identically distributed (i.i.d.) chi-
square random variables with df ¼ 1.27 Asymptotic p values can
be computed with Davies’ method or moment matching.18,22
We refer to these tests as burden-C if r1 ¼ r2 ¼ 1 and SKAT-C if
r1 ¼ r2 ¼ 0 (see Table 1).
Adaptive Sum Test of Rare- and Common-Variant
Effects
Above, we have chosen the weight parameter f such that rare and
common variants contribute equally to the overall test statistic.
An alternative approach is to compute p values for varying values
of f and use the minimum p value as a test statistic. This approach
can be potentially more powerful if the overall effect sizes of rare
and common variants are very different, for example, when only
rare variants in the region are associated or when only common
variants are associated with a trait. However, for this type of adap-
tive test, asymptotic p values cannot be obtained easily because oferican Journal of Human Genetics 92, 841–853, June 6, 2013 843
the potential correlation that exists between rare and common
variants.
Here, we propose the following adaptive approach instead. First,
we linearly transform Equation 2 via projection. The transformed
model is
g½EðYiÞ ¼ a0 þCiaþ ~X1ig1 þX2ig2; (Equation 3)
where ~X1 ¼ ð~X011;.; ~X
0
1nÞ0 ¼ ðIMÞX1 and M ¼ X2ðX02X2Þ1X02 is
an n 3 n projection matrix onto the column space of X2;
g1 ¼ ðg11;.;g1m1 Þ0 and g2 ¼ ðg21;.;g2m2 Þ0 are regression coeffi-
cients of the transformed model. Note that ~X1 corresponds to
the residuals by performing a linear regression of each component
of X1i on X2i. We assume that g1j is a random variable with
Eðg1jÞ ¼ 0, Varðg1jÞ ¼ w21jð1 fÞt, and corrðg1j;g1kÞ ¼ r1 for
different j and k. Similarly, g2j is a random variable with
Eðg2jÞ ¼ 0, Varðg2jÞ ¼ w22jft, and corrðg2j;g2kÞ ¼ r2. The null
hypothesis of b1 ¼ b2 ¼ 0 in the original Equation 2 is identical
to t ¼ 0 in the transformed Equation 3. A score test statistic with
given ðf; r1; r2Þ is
Qf;r1 ;r2 ¼ ð1 fÞðY bm0Þ0~K1;r1 ðY bm0Þ þ fðY bm0Þ0K2;r2 ðY bm0Þ
¼ ð1 fÞQrare þ fQcommon;
where ~K1;r1 ¼ ðIMÞX1W1Rr1W1X01ðIMÞ and K2;r2 ¼
X2W2Rr2W2X
0
2.
We propose the adaptive test,
T ¼ min
0%f%1
pfðr1; r2Þ;
where pfðr1; r2Þ is the p value for Qf;r1 ;r2. Test statistic T can be ob-
tained by a simple grid search, 0 ¼ f1 <. < fb ¼ 1. In simulation
studies and real data analysis, we used a grid of five values (0, 0.25,
0.50, 0.75, and 1). Because both Qrare and Q

common follow a
mixture of chi-square distributions and they are independent,
the null distribution of T can be easily obtained (see Appendix
A). We refer to these tests as burden-A if r1 ¼ r2 ¼ 1 and SKAT-A
if r1 ¼ r2 ¼ 0 (see Table 1).
In this approach, the rare variants are projected on the common
variants, a procedure that is similar to the practice of including
GWAS signals as covariates in order to test whether there is any
effect that rare variants contribute beyond the common variant
effects. An alternative approach would be to project common var-
iants on the rare variants. We evaluate both of these tests in our
simulation studies.
Fisher’s Combination Method
An alternative approach is to combine the p values from the rare-
and common-variant tests instead of combining test statistics. Let
prare and pcommon be the corresponding p values from the tests with
rare variants only and common variants only, respectively. Then,
we consider the following test statistic:
Q F;r1 ;r2 ¼ 2loge

prare
 2logepcommon:
Under the null hypothesis, both 2logeðprareÞ and
2logeðpcommonÞ are distributed as chi-square variables with 2 df.
Fisher’s combination method assumes that the statistics to be
combined are independent, and in that case, the distribution of
QF;r1 ;r2 is a chi-square with 4 df. However, because the rare- and
common-variant statistics might be correlated, the distribution
of QF;r1 ;r2 is more complicated. According to Brown,
28 it can be
approximated by a weighted chi-square distribution, cc2f , and a844 The American Journal of Human Genetics 92, 841–853, June 6, 2p value can be calculated by moment matching. More precisely,
we have
E

Q F;r1 ;r2
 ¼ 4 and
Var

Q F;r1 ;r2
 ¼ 4þ 2cov 2logeprare;2logepcommon;
where the covariance between 2logeðprareÞ and 2logeðpcommonÞ
is approximated by quadratic functions of the correlation between
the rare- and common-variant statistics, denoted by r. More pre-
cisely, as in Brown,28
cov
 2logeprare; 2logepcommon
¼
	
rð3:25þ 0:75rÞ 0%r%1
rð3:27þ 0:71rÞ 0:5%r%0
Although this result for the covariance assumes a joint multivar-
iate normal density for the variables, in our applications, this
approximation worked well for our situation (as a result of the
small correlation that exists between rare- and common-variant
statistics). The correlation (r) between the two quadratic forms
(for rare and common variants) can be calculated analytically
(see Appendix A). We approximate the distribution of QF;r1 ;r2 by
using cc2f , in which we estimate c and f by matching the first
two moments. This way, we obtain
f ¼ 2E

QF;r1 ;r2
2
Var

QF;r1 ;r2

c ¼ Var

QF;r1 ;r2

2E

QF;r1 ;r2
 :
We refer to these tests as burden-F if r1 ¼ r2 ¼ 1 and SKAT-F if
r1 ¼ r2 ¼ 0 (see Table 1).Results
Simulated Data
We simulated sequence data on 10,000 haplotypes in one
genomic region of length 1 Mb under a coalescent model
by using the software package COSI.29 The model used in
the simulations was the calibrated model for the European
population. For our purposes, we randomly sampled small
subregions of size 5 or 25 kb and simulated data sets with
n ¼ 1,000–5,000 individuals (equal number of cases and
controls).
We considered several disease models that involve a
mixture of common and rare disease risk variants. In our
simulated disease models (Table 2), we simulated rare risk
variants from those variants with a MAF% 0.01 and com-
mon risk variants with MAF > 0.01. For all models, we
assumed that a small percentage of the variants in a region
are associated with disease with effect sizes as described in
Table 2. Models 1–5 assume that all disease-associated var-
iants confer risk, whereas model 6 assumes a mixture of
risk and protective variants. Because the number of com-
mon variants in a given region is generally much smaller
than the number of rare variants, in order to increase the
contribution from common variants, for model 2, we
assumed that although only 10%–30% of rare variants
are associated, 50% of the common variants are associated
with disease.013
Table 2. Six Disease Models
Model Description
1 10%–30% of rare variants have an ORR ¼ 2
10%–30% of common variants have an ORC ¼ 1.1
2 10%–30% of rare variants have an ORR¼ 2
50% of common variants have an ORC ¼ 1.1
3 10%–30% of all variants have an OR ¼ e0:2jðlog10ðMAFÞÞj
4 10%–30% of rare variants have an ORR ¼ 2
no common associated variants
5 10%–30% of common variants have an ORC ¼ 1.2
no rare associated variants
6 10%–30% of rare variants have an ORR ¼ 2
10%–30% of common variants have an ORC ¼ 1.2
30% of associated variants are protective (and have an
ORR ¼ 0.5 and an ORC ¼ 0.84)
Abbreviations are as follows: ORR, OR for disease-associated variants with
MAF % 0.01; and ORC, OR for disease-associated variants with MAF > 0.01.For a dichotomous trait, we assumed the following logis-
tic model:
logit½PðYi ¼ 1Þ ¼ a0 þ b1Xi1 þ.þ bmXim:
a0 was chosen such that the disease prevalence was 0.05.
We compared the proposed combination tests with three
of the most commonly used tests—burden, SKAT, and
CMC11—as well as the SKAT test with no variant weighting
(see Table 1 for a description of these tests).Table 3. Type 1 Error for the Proposed RC-SKAT Combination Tests
Length n a Burden-A SKAT-A
5 kb 1,000 5.0 3 102 4.9 3 102 3.9 3 102
1.0 3 102 9.6 3 103 7.1 3 103
1.0 3 104 8.2 3 105 6.1 3 105
2.5 3 106 1.6 3 106 2.2 3 106
5 kb 2,000 5.0 3 102 4.9 3 102 4.3 3 102
1.0 3 102 9.8 3 103 8.2 3 103
1.0 3 104 8.7 3 105 8.6 3 105
2.5 3 106 1.9 3 106 2.2 3 106
25 kb 1,000 5.0 3 102 4.9 3 102 3.7 3 102
1.0 3 102 9.8 3 103 6.6 3 103
1.0 3 104 9.1 3 105 6.6 3 105
2.5 3 106 1.7 3 106 2.1 3 106
25 kb 2,000 5.0 3 102 5.0 3 102 4.1 3 102
1.0 3 102 9.9 3 103 7.8 3 103
1.0 3 104 9.8 3 105 8.9 3 105
2.5 3 106 2.4 3 106 3.2 3 106
The AmType 1 Error
To evaluate the type 1 error for the proposed combination
(RC-SKAT) methods, we simulated data under the null
model (logit½PðYi ¼ 1Þ ¼ a0) for n ¼ 1,000–2,000 and
regions of size 5 and 25 kb (we did not simulate the
n ¼ 5,000 scenario because of the prohibitive computa-
tional cost for very small significance values). Results
based on 107 simulations are shown in Table 3. The
type 1 error for all the proposed methods agrees well
with the expectation for a ¼ {0.05, 0.01, 0.0001, 2.5 3
106}. Note that a ¼ 2.5 3 106 is an exome-wide
significance level of 0.05 when 20,000 genes are simulta-
neously evaluated.
Power with Different Frequency Cutoffs
Because the proposed combination tests require an explicit
partition of the genetic variants in a region into rare and
common variants, we first evaluated the sensitivity of
using several different separation cutoffs to the true dis-
ease model. We compared the power of the proposed
methods under three disease models when using different
separation cutoffs. The disease models are as follows. The
first two are disease models 1 and 3 in Table 2. The third
model is similar to model 1 in Table 2 but has the same
odds ratio (OR) of 1.5 for all risk variants (hence, there is
no difference in effect size between rare and common
risk variants).
Furthermore, for each of these models, we considered
four possible scenarios: (1) all risk variants have a MAF <
0.005, (2) all risk variants have MAF < 0.01, (3) all risk var-
iants haveMAF< 0.05, and (4) all risk variants haveMAF>
0.05. For example, for model 1 and scenario (1) above, allBurden-C SKAT-C Burden-F SKAT-F
4.9 3 102 4.6 3 102 5.0 3 102 4.9 3 102
9.7 3 103 8.8 3 103 1.0 3 102 1.0 3 102
8.6 3 105 7.4 3 105 1.3 3 104 1.3 3 104
1.6 3 106 1.9 3 106 2.6 3 106 3.0 3 106
4.9 3 102 4.7 3 102 5.0 3 102 4.9 3 102
9.8 3 103 9.2 3 103 1.0 3 102 9.9 3 103
8.9 3 105 8.2 3 105 1.1 3 104 1.2 3 104
1.8 3 106 1.4 3 106 4.0 3 106 3.4 3 106
4.9 3 102 4.6 3 102 5.0 3 102 4.9 3 102
9.7 3 103 8.6 3 103 1.1 3 102 9.9 3 103
8.3 3 105 6.9 3 105 1.5 3 104 1.3 3 104
1.4 3 106 1.7 3 106 4.2 3 106 1.9 3 106
4.9 3 102 4.7 3 102 5.0 3 102 4.8 3 102
9.8 3 103 9.2 3 103 1.0 3 102 9.9 3 103
1.0 3 104 8.6 3 105 1.4 3 104 1.2 3 104
2.1 3 106 2.0 3 106 4.8 3 106 3.9 3 106
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Model 1, Burden-C, l = 25 kb, PC = 0.3 Figure 1. Power of the Burden-C Test
with Different Frequency Thresholds to
Separate Rare from Common Variants
Power (a ¼ 2.5 3 106) of using different
frequency thresholds to separate rare and
common variants (fixed values 0.005,
0.01, and 0.05 versus 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
) for the pro-
posed combination method burden-C for
model 1 (in Table S1) and for n ¼ 500,
1,000, 2,000, and 5,000 in a region of size
25 kb. The proportion of associated vari-
ants (PC) in the region is 30%. The
sample-dependent threshold 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
is:
0.03 (n ¼ 500), 0.02 (n ¼ 1,000), 0.015
(n ¼ 2,000), and 0.01 (n ¼ 5,000).risk variants have a MAF < 0.005 and an OR ¼ 2. A sum-
mary of these models is given in Table S1, available online.
We compared the power of the proposed combination
methods (e.g., burden-C and SKAT-C) when using conven-
tional cutoffs (such as 0.005, 0.01, and 0.05) to separate
rare and common variants versus the sample-dependent
cutoff of 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
. All power calculations are based on
1,000 simulated data sets for each scenario.
Results for the first model, with a 25 kb genetic region,
and the burden-C test are shown in Figure 1 (the results
for the SKAT-C test are in Figure S1; additional results,
including other simulation scenarios, are given in the
Supplemental Data). The optimal cutoff ultimately de-
pends both on sample size (n) and on the true disease
model (i.e., the joint distribution of true risk allele fre-
quencies and effect sizes, which is unknown to us).
When sample sizes are large (e.g., n ¼ 5,000), the optimal
threshold correlates well with the underlying disease
model. For example, for model 1, true risk variants have
an OR ¼ 2 if their MAF % 0.01 and an OR ¼ 1.1 if their
MAF > 0.01. For n ¼ 5,000, if the risk variants have a
MAF % 0.005 or 0.01, the best separation cutoffs are
0.005 and 0:01 ¼ 1= ﬃﬃﬃﬃﬃﬃ2np ; using 0.05 as a cutoff causes a
significant loss in power (Figures 1 and S1). Conversely,
when all risk variants have a MAF > 0.05, a cutoff of 0.05
tends to perform the best. In spite of this expected depen-
dence of the optimal separation threshold on the true
disease model when sample sizes are large, the sample-
dependent threshold tends to perform consistently well
across the simulated scenarios. When sample sizes are
small (e.g., n ¼ 500), the dependence of the best cutoff
on the true disease model is less clear, but because of the
increased variance in the observed frequencies of risk
alleles, a sample-dependent cutoff as proposed here can
be considered. In what follows, for the sake of fixation,
we will report power for these combination tests by using
only the 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
threshold.846 The American Journal of Human Genetics 92, 841–853, June 6, 2013Comparison of Power across
Different Tests
In Figures 2 and 3, we report the
power of the proposed RC-SKAT
methods and of the existing methods(burden test, SKAT, and CMC) for the disease models in
Table 2 and genetic regions of size 25 kb. We also compare
with the power of the original SKAT test, but without
variant weighting. Overall, for all the models that include
common associated variants (models 1–3, 5, and 6), the
combination methods outperform existing methods,
oftentimes in a substantial way. Even when all disease-
associated variants are rare (model 4), the proposed combi-
nationmethods perform similarly to the existingmethods,
suggesting that applying the proposed methods in that
case causes no or little efficiency loss (Figure 3A). However,
when all risk variants are common (model 5), the RC-SKAT
approaches outperform the existing methods substantially
(Figure 3B). The proposed combination methods outper-
form CMC across all six models. The same is true when
they are compared with the original SKAT test with no
variant weighting.
For models 1–4, which include only risk variants, SKAT
tests tend to be more powerful than the corresponding
burden tests when the proportion of risk variants is small
(e.g., 10%); however, burden tests become more powerful
than SKAT tests when the proportion of risk variants is
large (e.g., 30% or more). Note that for models 1–3, which
include both rare and common risk variants, SKAT-F
(Fisher) test tends to have better power than the burden-
F test regardless of whether the proportion of associated
variants is 10% or 30%. For model 5, which includes
only common risk variants, the SKAT tests tend to perform
better than the burden tests regardless of the proportion of
risk variants (probably as a result of the fact that only a
small proportion of variants in a given region are com-
mon). The same holds true for model 6, which includes
both risk and protective variants (Figure 3C). Note that
CMC also performs better than existing burden and
SKAT tests for this model. Although the CAST rare-variant
statistic employed by CMC loses power when there is a
mixture of risk and protective variants in the region, the
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Figure 2. Power for Models 1–3 in 25 kb
Regions
Power (a ¼ 2.5 3 106) of the tests in
Table 1 for a region of size 25 kb (l ¼
25 kb) across disease models 1–3 in Table 2
for n ¼ 1,000, 2,000, and 5,000 and two
different values for the proportion of asso-
ciated variants in a region: 10% (i.e., PC ¼
0.1) or 30% (i.e., PC ¼ 0.3).Hotelling’s statistic (which underlies the CMC test) for rare
and common variants performs well in such settings. The
original SKAT test without variant weighting tends to
perform worse than the proposed combination tests,
with the exception of model 5, which only includes com-
mon risk variants. However, compared with the proposed
tests, SKAT without weighting suffers substantial loss of
power for the remaining five models, and especially for
model 4, which has only rare risk variants.
The adaptive tests (burden-A and SKAT-A, obtained by
either the projection of rare variants over common variants
or the other way around) tend to perform worse than the
burden-C and SKAT-C tests (see Figures S2 and S3).
Results for a region of size 5 kb were similar and are
shown in Figures S6 and S7.
Crohn Disease NOD2 Sequence Data
We applied our RC-SKAT methods to sequencing data for
NOD2 (MIM 605956) from 453 Crohn disease cases and
103 healthy controls.30 In total, 60 single-nucleotide vari-
ations, nine of which have a frequency greater than 5%,
have been identified (in exons and all of the intron-exon
junctions). Because only pooled frequency counts were
available for each variant, we generated simulated
sequencing data for 453 cases and 103 controls, consistent
with the observed counts, and we assumed the correlationThe American Journal of Humastructure between the common vari-
ants as in HapMap 3 (CEU [Utah resi-
dents with ancestry from northern
and western Europe from the CEPH
collection] population). Rare variants
were assumed to be independent of
each other and the common variants.
We first performed a common-
variant analysis by using the trend
test in PLINK;31 six of the nine com-
mon variants were found to be associ-
ated (p < 0.05), and the smallest
p value was 1.1 3 104 (Table 4). We
then performed gene-based tests. We
applied three of the commonly used
tests for sequence data (burden,
SKAT, and CMC), the burden and
SKAT tests without variant weighting,
and the new RC-SKAT tests to this
case-control data set. We used
different frequency thresholds,ﬃﬃﬃﬃﬃﬃp
including the proposed 1= 2n ¼ 0:029, 0.01, and 0.05,
to separate the variants into rare and common. The results
are given in Table 5. As shown, several of our combination
tests resulted in exome-wide-significant p values (e.g., the p
value for SKAT-C was 1.7 3 107 when the threshold was
1=
ﬃﬃﬃﬃﬃﬃ
2n
p
), as did CMC (p value of 1.73 107). Both the orig-
inal burden and SKAT tests produced only modest p values
(>5.03 104). Similarly, the original burden and SKAT tests
withno variantweighting resulted in p values> 1.03 105.
Because it is known that both common and rare variants in
NOD2 independently affect disease risk2 (see also Table 4), it
is not surprising that combination tests such as those dis-
cussed here perform better than existing tests, such as the
burden and SKAT tests, which focus primarily on detecting
rare risk variants.
Autism LRP2 Sequence Data
We then applied the proposed methods to a second
sequencing data set for ASDs. LRP2 (MIM 600073) is a
gene that resides in a region linked to ASD on chromosome
2q. Recently, on the basis of three independent data sets,
Ionita-Laza et al.32 have found evidence that rare variants
associated with ASD cluster in a small region of this
gene. Moreover, three publications focused on de novo
mutations have reported additional supporting evidence
for the role of this gene in ASD and intellectualn Genetics 92, 841–853, June 6, 2013 847
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Figure 3. Power for Models 4–6 in 25 kb
Regions
Power (a ¼ 2.5 3 106) of the tests in
Table 1 for a region of size 25 kb (l ¼
25 kb) across disease models 4–6 in Table 2
for n ¼ 1,000, 2,000, and 5,000 and two
different values for the proportion of asso-
ciated variants in a region: 10% (i.e., PC ¼
0.1) or 30% (i.e., PC ¼ 0.3).disability.33–35 In Ionita-Laza et al.,32 we observed that, in
addition to the cluster of rare disease-associated variants,
common variants are also associated with ASD. Hence,
for LRP2, there is evidence from different studies for the
contribution of de novo, rare, and common variants to
autism.
We applied the RC-SKAT tests in Table 1 to a data set con-
sisting of 430 cases and 379 controls sequenced in the
exonic regions of LRP2 (more details about this data set
are reported in Appendix A). The results of several existing
tests and the proposed RC-SKAT tests are given in Table 5.
As shown, the existing tests, including burden, SKAT and
CMC, resulted in marginally nonsignificant p values for
this gene, suggesting no significant rare-variant effects.
The proposed combination tests resulted in several signifi-
cant p values, given that the signals in this gene mainly
come from common variants. For example, the p value
for burden-C was 6.1 3 104 when T ¼ 1= ﬃﬃﬃﬃﬃﬃ2np ¼ 0:024,
whereas for SKAT-C, the corresponding p value was 2.3 3
102. Because the common LRP2 variants associated with
ASD tend to have similar effect sizes and the same direction
of effect, it is expected that the burden tests perform better
than the SKAT tests. The original burden and SKAT tests
without weighting performed similarly to the proposed
combination tests for this gene.848 The American Journal of Human Genetics 92, 841–853, June 6, 2013Discussion
We have proposed sequence kernel
association tests that test for the
contribution of both rare and com-
mon genetic variants to risk of com-
plex diseases. Unlike most existing
tests that upweight the contribution
of rare variants and downweight the
contribution of common variants,
the proposed tests assess the contribu-
tion of rare and common variants
separately and then combine the
corresponding test statistics or the
p values by using either an equal
weight or an adaptive weight. As
with the existing burden and SKAT
tests, it is easy to incorporate covari-
ates, including principal components,
to adjust for population stratification.
The proposed RC-SKAT tests are
based on first partitioning all the var-iants into rare and common variants. Such partitioning is
based on a frequency threshold. Usually, this threshold is
chosen as a fixed value, e.g., 0.01 or 0.05. We have sug-
gested here another possible threshold that depends on
the sample size, namely, 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
. Therefore, when the sam-
ple size is small, the separating threshold will be higher
than for a larger sample size. Although this threshold is
clearly not optimal in that it only depends on sample
size and not on the underlying effect-size distribution, it
can serve as a lower bound on the possible cutoffs to be
considered. This ensures that variants that occur only a
few times in amodest data set are not classified as common
(which can lead to loss of power). Furthermore, this
threshold can be used for identifying additional ‘‘com-
mon’’ variants (e.g., those variants that have a frequency
below 0.01 and that are traditionally defined as rare) that
can be tested individually for their effect on the trait. In
practice, we suggest using this sample-size-dependent
threshold, along with several larger fixed thresholds.
Although it is possible to adaptively select the threshold
(as in Price et al.13), such an approach requires permuta-
tions that are computationally intensive and might be
problematic when there are covariates to be adjusted for.
The idea of separating variants into rare and common
has been proposed before, most notably in the CMC test.
Table 4. p Values from the Cochran-Armitage Trend Test for the
Common NOD2 Variants Significantly Associated with Crohn
Disease
NOD2 Variant f A f U p OR
c.3020insC 0.10 0.02 0.0001 5.98
c.802C>T 0.41 0.27 0.0008 1.84
c.1377C>T 0.41 0.28 0.0016 1.79
c.2722G>C 0.06 0.01 0.0035 6.59
c.2104C>T 0.10 0.04 0.0074 2.65
c.33G>T in 50 UTR 0.41 0.33 0.033 1.46
Significance is defined as p < 0.05. Abbreviations are as follows: fA, estimated
frequency of minor allele in cases; fU , estimated frequency of minor allele in
controls; and OR, estimated odds ratio.
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3We have compared the proposed combination tests with
CMC and have shown that the proposed tests tend to
have higher power than CMC uniformly across the simu-
lated scenarios. CMC loses power especially when the re-
gions tested are large (e.g., 25 kb) because of the increased
degrees of freedom for Hotelling’s T2 and as such resulted
in a nonsignificant p value for LRP2 (a large gene with
length ~200 kb). More recently, Cardin et al.36 have pro-
posed a hierarchical modeling approach for joint associa-
tion between rare and common variants and binary traits.
This approach is based on averaging over prior distribu-
tions of effect sizes, which are unknown to us, and there-
fore performance might be sensitive to such assumptions.
Furthermore, the approach is computationally intensive,
which makes it difficult to evaluate in large-scale power
simulations of the type performed here.We have, however,
considered several additional combination tests, including
a test based on the minimum of p values from a burden or
SKAT rare-variant test and individual p values for common
variants (more details are in Appendix A). However, none
of these more straightforward alternatives resulted in
better power than the new tests we have proposed here
(Figures S4 and S5).
Two of the proposed combination methods (burden-A
and SKAT-A) are based on the adaptive approach that
selects the optimal weight for combining common- and
rare-variant test statistics. To compute p values analyti-
cally, it relies on the projection of the common-variant
information out from the rare-variant information.
Although the projection allows fast computation, it can
weaken the association signal. In our simulation experi-
ments, these approaches tended to be less powerful than
the other combination methods. In practice, we suggest
using burden-C and SKAT-C or alternatively burden-F
and SKAT-F, similar to the suggestion made by others37,38
of using both a linear (i.e., burden) test and a quadratic
(i.e., SKAT) test in the context of association testing with
rare variants.
The RC-SKAT tests are applicable to population-based
designs with binary or quantitative traits. Both burden
tests and SKAT tests have been recently extended toThe American Journal of Human Genetics 92, 841–853, June 6, 2013 849
Table A1. Simulation Models for Investigating the Variance
Explained by Rare versus Common Variants
Model Description
1 10% of rare variants have an ORR ¼ 2
10% of common variants have an ORC ¼ 1.1
2 10% of rare variants have an ORR¼ 2
10% of common variants have an ORC ¼ 1.2
3 10% of all variants have an OR ¼ e0:2jðlog10ðMAFÞÞjfamily-based designs,39 and hence, the proposed combina-
tion tests are also applicable to family-based designs. Such
family-based tests are transmission-disequilibrium types of
tests, and are hence robust to population stratification.
WES is only able to survey variation in coding regions,
thereby missing a lot of the variation in noncoding re-
gions. It is not uncommon for a study to contain both
GWAS data and WES data on the same individuals. The
proposed methods can take advantage of the common
variation on the GWAS arrays and combine with WES
data to increase the power to identify genes containing
variation associated with complex diseases. Furthermore,
the proposed tests are applicable to deep-resequencing
data for GWAS loci.
In summary, we have proposed tests for both rare- and
common-variant effects and have shown that they are
more powerful than existing groupwise association tests
under a wide range of scenarios. The proposed tests are
implemented in the software package SKAT.0.005 0.010 0.015 0.020 0.0250
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Variance Explained: Common vs. RareAppendix A
Variance Explained by Common versus Rare Risk
Variants
Although the relative contribution of rare and common
variants to risk of complex diseases is unknown for most
complex traits, it is expected that both common and rare
variants are important. Even though rare variants are
more likely to be functional and are expected to have
higher effects than common variants, common variants
can account for a substantial proportion of the genetic
variance. In commonly used simulation experiments
with 25 kb genetic regions that include 10% rare and com-
mon disease risk variants (Table A1), the genetic variance
explained by common variants can be higher than that
explained by rare variants (Figure A1).0.005 0.010 0.015 0.020 0.025
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Figure A1. Variance Explained by Rare versus Common Risk-
Associated Variants
Variance explained by common associated variants versus rare
associated variants in a 25 kb region (based on 100 random re-
gions). Ten percent of all variants in the region are associated
with the trait. Each dot corresponds to one random 25 kb region.
Variance explained by common variants (MAF > 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
) is on the
y axis, and variance explained by rare variants (MAF < 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
) is
on the x axis.Asymptotic Null Distribution of the Adaptive Sum
Test of Rare- and Common-Variant Effects
It is easy to show that
Qrare ¼ k1 
Pm1
q¼1
l1qc
2
1 and
Qcommon ¼ k2 
Pm2
q¼1
l2qc
2
1;
where fl1qg are eigenvalues of P1=2K1;r1P1=2 and fl2qg are
eigenvalues of P1=2~K2;r2P
1=2, in which P ¼ bV1bV1 ~Cð~C0 bV1 ~CÞ1 ~C0 bV1, where ~C is an n3ðqþ 1Þ matrix
equal to [1 C] and bV is a diagonal matrix of the variance
of Y under the null hypothesis. We approximate the
mixture of chi-square distributions by using moment
matching. If we let qðfkÞ be the ð1 TÞth percentile of
the distribution of Qfk ;r1;r2 for each fk in our grid, then
the p value of T can be calculated as850 The American Journal of Human Genetics 92, 841–853, June 6, 2p ¼ 1 P
h
Qf1 ;r1 ;r2 < qðf1Þ;.;Qfb ;r1 ;r2 < qðfbÞ
i
¼ 1 P½ð1 f1Þk1 þ f1k2 < qðf1Þ;.; ð1 fbÞk1
þ fbk2 < qðfbÞ
¼ 1 P

k1 < min
0%f%1
qðfÞ  fk2
1 f

¼ 1 E

P


k1 < min
0%f%1
qðfÞ  fk2
1 f j k2

:013
This can be obtained by computationally efficient one-
dimensional integration.
Correlation between Two Quadratic Forms
We use the following relations to calculate the correlation
between two quadratic forms. Let us assume that E½Y ¼ 0.
Let S ¼ Var½Y. Let A and B be real and symmetric n 3 n
matrices. Then
E½Y 0AY ¼ trðASÞ and
Cov½Y 0AY,Y 0BY ¼ 2trðASBSÞ:
Data Generation and Processing for the Broad
AASC Data
The ASD case-control data set has been sequenced as part
of the American Recovery and Reinvestment Act (ARRA)
Autism Sequencing Collaboration (AASC).WES of the sam-
ples was carried out at the Broad Institute as follows.
The SureSelect v.2 Human exon Agilent 38Mb exon-cap-
ture kit was used for library enrichment (Agilent Technol-
ogies). After capture, another round of ligation-mediated
PCR was performed for increasing the quantity of DNA
available for sequencing. All libraries were sequenced
with an Illumina HiSeq2000 according to the manufac-
turer’s (Illumina) instructions for paired-end 100 bp reads.
After sequencing, the data were put through a computa-
tional pipeline for WES data processing and analysis
according to the general workflow adopted by the 1000
Genomes Project.40 First, the alignment of raw sequence
reads to the human reference genome sequence (NCBI
GRCh37) was performed with a fast lightweight Burrows-
Wheeler Aligner41 and a binary version of SAMtools.42
The Genome Analysis Toolkit (GATK)43 was then used for
base-quality recalibration and local realignment for mini-
mizing base-calling error and mapping error, respectively.
SNPs were called with GATK for all samples jointly. Only
variants passing GATK standard filters were considered
for analysis. Resulting calls were annotated with Snpeff44
and GATK VariantAnnotator tools.
Additional Gene-Based Tests
In addition to the tests described in Table 1, we also consid-
ered several additional tests, as follows:
1. SKAT-rare: the original SKAT test restricted to rare
variants (those variants with MAF < 1=
ﬃﬃﬃﬃﬃﬃ
2n
p
).
2. SKAT-common: the original SKAT test restricted to
common variants (those variants with MAF >
1=
ﬃﬃﬃﬃﬃﬃ
2n
p
) and with weight Betaðbpj ;0:5;0:5Þ.
3. SKAT-NW: the original SKAT test for all variants in a
region and with no variant weighting.
4. LRT-common: the likelihood ratio test with common
variants only.
5. LRT: in which the minimum of the p values of SKAT-
rare and LRT-common tests is multiplied by 2.
6. Min-p: in which the minimum of the p values of
SKAT-rare and of common variants is multiplied byThe Am2 (calculating the p value for common variants re-
quires that the minimum p value of the p values
for individual common variants be adjusted for the
effective number of variants, as described in Gao
et al.45).
For LRTandMin-p, theminimumof the p values of com-
mon and rare variants tests is multiplied by 2 so that the
number of tests can be adjusted for. Because the correlation
between rare and common variants tends to be low, this
adjustment is largely accurate.Supplemental Data
Supplemental Data include 32 figures and 1 table and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
The research was partially supported by National Science Founda-
tion grant DMS-1100279 and National Institutes of Health grants
R01MH095797 and 1R03HG005908 (to I.I.-L.), National Institutes
of Health grant K99-HL113164 (to S.L.), a Seaver Foundation grant
and National Institutes of Health grants MH089025 and
MH100233 (to J.D.B.), and National Institutes of Health grants
R37 CA076404 and P01CA134294 (to S.L. and X.L.).
Received: January 28, 2013
Revised: March 20, 2013
Accepted: April 18, 2013
Published: May 16, 2013Web Resources
The URLs for data presented herein are as follows:
HapMap 3, http://www.sanger.ac.uk/resources/downloads/
human/hapmap3.html
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/omim
PLINK, http://pngu.mgh.harvard.edu/~purcell/plink/
SKAT, www.hsph.harvard.edu/xlin/software.htmlReferences
1. Kiezun, A., Garimella, K., Do, R., Stitziel, N.O., Neale, B.M.,
McLaren, P.J., Gupta, N., Sklar, P., Sullivan, P.F., Moran, J.L.,
et al. (2012). Exome sequencing and the genetic basis of com-
plex traits. Nat. Genet. 44, 623–630.
2. Rivas, M.A., Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y.,
Zhang, C.K., Boucher, G., Ripke, S., Ellinghaus, D., Burtt, N.,
et al.; National Institute of Diabetes and Digestive Kidney
Diseases Inflammatory Bowel Disease Genetics Consortium
(NIDDK IBDGC); United Kingdom Inflammatory Bowel
Disease Genetics Consortium; International Inflammatory
Bowel Disease Genetics Consortium. (2011). Deep resequenc-
ing of GWAS loci identifies independent rare variants associ-
ated with inflammatory bowel disease. Nat. Genet. 43,
1066–1073.
3. Asselbergs, F.W., Guo, Y., van Iperen, E.P., Sivapalaratnam, S.,
Tragante, V., Lanktree, M.B., Lange, L.A., Almoguera, B.,erican Journal of Human Genetics 92, 841–853, June 6, 2013 851
Appelman, Y.E., Barnard, J., et al.; LifeLines Cohort Study.
(2012). Large-scale gene-centric meta-analysis across 32
studies identifies multiple lipid loci. Am. J. Hum. Genet. 91,
823–838.
4. Diogo, D., Kurreeman, F., Stahl, E.A., Liao, K.P., Gupta, N.,
Greenberg, J.D., Rivas, M.A., Hickey, B., Flannick, J., Thomson,
B., et al.; Consortium of Rheumatology Researchers of North
America; Rheumatoid Arthritis Consortium International.
(2013). Rare, low-frequency, and common variants in the
protein-coding sequence of biological candidate genes from
GWASs contribute to risk of rheumatoid arthritis. Am. J.
Hum. Genet. 92, 15–27.
5. Visscher, P.M., Brown, M.A., McCarthy, M.I., and Yang, J.
(2012). Five years of GWAS discovery. Am. J. Hum. Genet.
90, 7–24.
6. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders,
A.K., Nyholt, D.R., Madden, P.A., Heath, A.C., Martin, N.G.,
Montgomery, G.W., et al. (2010). Common SNPs explain a
large proportion of the heritability for human height. Nat.
Genet. 42, 565–569.
7. Purcell, S.M., Wray, N.R., Stone, J.L., Visscher, P.M., O’Dono-
van, M.C., Sullivan, P.F., and Sklar, P.; International Schizo-
phrenia Consortium. (2009). Common polygenic variation
contributes to risk of schizophrenia and bipolar disorder.
Nature 460, 748–752.
8. Klei, L., Sanders, S.J., Murtha,M.T., Hus, V., Lowe, J.K.,Willsey,
A.J., Moreno-De-Luca, D., Yu, T.W., Fombonne, E., Gesch-
wind, D., et al. (2012). Common genetic variants, acting addi-
tively, are a major source of risk for autism. Mol Autism 3, 9.
9. Lee, S.H., DeCandia, T.R., Ripke, S., Yang, J., Sullivan, P.F.,
Goddard, M.E., Keller, M.C., Visscher, P.M., and Wray, N.R.;
Schizophrenia Psychiatric Genome-Wide Association Study
Consortium (PGC-SCZ); International Schizophrenia Con-
sortium (ISC); Molecular Genetics of Schizophrenia Collabora-
tion (MGS). (2012). Estimating the proportion of variation in
susceptibility to schizophrenia captured by common SNPs.
Nat. Genet. 44, 247–250.
10. Agresti, A. (2002). Categorical Data Analysis, Second Edition
(Gainesville, FL: John Wiley & Sons).
11. Li, B., and Leal, S.M. (2008). Methods for detecting associa-
tions with rare variants for common diseases: application to
analysis of sequence data. Am. J. Hum. Genet. 83, 311–321.
12. Madsen, B.E., and Browning, S.R. (2009). A groupwise associ-
ation test for rare mutations using a weighted sum statistic.
PLoS Genet. 5, e1000384.
13. Price, A.L., Kryukov, G.V., de Bakker, P.I., Purcell, S.M., Staples,
J., Wei, L.J., and Sunyaev, S.R. (2010). Pooled association tests
for rare variants in exon-resequencing studies. Am. J. Hum.
Genet. 86, 832–838.
14. Liu, D.J., and Leal, S.M. (2010). A novel adaptive method for
the analysis of next-generation sequencing data to detect
complex trait associations with rare variants due to gene
main effects and interactions. PLoS Genet. 6, e1001156.
15. Han, F., and Pan, W. (2010). A data-adaptive sum test for
disease association with multiple common or rare variants.
Hum. Hered. 70, 42–54.
16. Ionita-Laza, I., Buxbaum, J.D., Laird, N.M., and Lange, C.
(2011). A new testing strategy to identify rare variants with
either risk or protective effect on disease. PLoS Genet. 7,
e1001289.
17. Neale, B.M., Rivas, M.A., Voight, B.F., Altshuler, D., Devlin, B.,
Orho-Melander, M., Kathiresan, S., Purcell, S.M., Roeder, K.,852 The American Journal of Human Genetics 92, 841–853, June 6, 2and Daly, M.J. (2011). Testing for an unusual distribution of
rare variants. PLoS Genet. 7, e1001322.
18. Wu, M.C., Lee, S., Cai, T., Li, Y., Boehnke, M., and Lin, X.
(2011). Rare-variant association testing for sequencing data
with the sequence kernel association test. Am. J. Hum. Genet.
89, 82–93.
19. Lin, D.Y., and Tang, Z.Z. (2011). A general framework for de-
tecting disease associations with rare variants in sequencing
studies. Am. J. Hum. Genet. 89, 354–367.
20. Tzeng, J.Y., Zhang, D., Pongpanich, M., Smith, C., McCarthy,
M.I., Sale, M.M., Worrall, B.B., Hsu, F.C., Thomas, D.C., and
Sullivan, P.F. (2011). Studying gene and gene-environment
effects of uncommon and common variants on continuous
traits: a marker-set approach using gene-trait similarity regres-
sion. Am. J. Hum. Genet. 89, 277–288.
21. Lee, S., Emond, M.J., Bamshad, M.J., Barnes, K.C., Rieder, M.J.,
Nickerson, D.A., Christiani, D.C., Wurfel, M.M., and Lin, X.;
NHLBI GO Exome Sequencing Project—ESP Lung Project
Team. (2012). Optimal unified approach for rare-variant asso-
ciation testing with application to small-sample case-control
whole-exome sequencing studies. Am. J. Hum. Genet. 91,
224–237.
22. Lee, S., Wu, M.C., and Lin, X. (2012). Optimal tests for rare
variant effects in sequencing association studies. Biostatistics
13, 762–775.
23. Chen, L.S., Hsu, L., Gamazon, E.R., Cox, N.J., and Nicolae,
D.L. (2012). An exponential combination procedure for set-
based association tests in sequencing studies. Am. J. Hum.
Genet. 91, 977–986.
24. Alexander, R.P., Fang, G., Rozowsky, J., Snyder, M., and
Gerstein, M.B. (2010). Annotating non-coding regions of the
genome. Nat. Rev. Genet. 11, 559–571.
25. Cai, T., Jeng, J., and Jin, J. (2011). Optimal detection of hetero-
geneous and heteroscedastic mixtures. Journal of the Royal
Statistical Society: Series B (Statistical Methodology) 73,
629–662.
26. Davies, R.B. (1977). Hypothesis testing when a nuisance
parameter is present only under the alternative. Biometrika
64, 247–254.
27. Zhang, D., and Lin, X. (2003). Hypothesis testing in semipara-
metric additive mixed models. Biostatistics 4, 57–74.
28. Brown, M. (1975). 400: A method for combining non-inde-
pendent, one-sided tests of significance. Biometrics 31,
987–992.
29. Schaffner, S.F., Foo, C., Gabriel, S., Reich, D., Daly, M.J., and
Altshuler, D. (2005). Calibrating a coalescent simulation of
human genome sequence variation. Genome Res. 15, 1576–
1583.
30. Lesage, S., Zouali, H., Ce´zard, J.P., Colombel, J.F., Belaiche, J.,
Almer, S., Tysk, C., O’Morain, C., Gassull, M., Binder, V.,
et al.; EPWG-IBD Group; EPIMAD Group; GETAID Group.
(2002). CARD15/NOD2 mutational analysis and genotype-
phenotype correlation in 612 patients with inflammatory
bowel disease. Am. J. Hum. Genet. 70, 845–857.
31. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
32. Ionita-Laza, I., Makarov, V., and Buxbaum, J.D.; ARRA Autism
Sequencing Consortium. (2012). Scan-statistic approach iden-
tifies clusters of rare disease variants in LRP2, a gene linked013
and associated with autism spectrum disorders, in three data-
sets. Am. J. Hum. Genet. 90, 1002–1013.
33. Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rose-
nbaum, J., Yamrom, B., Lee, Y.H., Narzisi, G., Leotta, A., et al.
(2012). De novo gene disruptions in children on the autistic
spectrum. Neuron 74, 285–299.
34. O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N.,
Coe, B.P., Levy, R., Ko, A., Lee, C., Smith, J.D., et al. (2012).
Sporadic autism exomes reveal a highly interconnected pro-
tein network of de novo mutations. Nature 485, 246–250.
35. de Ligt, J., Willemsen, M.H., van Bon, B.W., Kleefstra, T.,
Yntema, H.G., Kroes, T., Vulto-van Silfhout, A.T., Koolen,
D.A., de Vries, P., Gilissen, C., et al. (2012). Diagnostic exome
sequencing in persons with severe intellectual disability.
N. Engl. J. Med. 367, 1921–1929.
36. Cardin, N.J., Mefford, J.A., and Witte, J.S. (2012). Joint associ-
ation testing of common and rare genetic variants using hier-
archical modeling. Genet. Epidemiol. 36, 642–651.
37. Derkach, A., Lawless, J.F., and Sun, L. (2012) Assessment of
Pooled Association Tests for Rare Genetic Variants within a
Unified Framework. arXiv, arXiv:1205.4079, http://arxiv.org/
abs/1205.4079.
38. Basu, S., and Pan,W. (2011). Comparison of statistical tests for
disease association with rare variants. Genet. Epidemiol. 35,
606–619.
39. Ionita-Laza, I., Lee, S., Makarov, V., Buxbaum, J.D., and Lin, X.
(2013). Family-based association tests for sequence data, and
comparisons with population-based association tests. Eur. J.
Hum. Genet. http://dx.doi.org/10.1038/ejhg.2012.308.The Am40. DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire,
J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A.,
Hanna, M., et al. (2011). A framework for variation discovery
and genotyping using next-generation DNA sequencing data.
Nat. Genet. 43, 491–498.
41. Li, H., and Durbin, R. (2010). Fast and accurate long-read
alignment with Burrows-Wheeler transform. Bioinformatics
26, 589–595.
42. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer,
N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome
Project Data Processing Subgroup. (2009). The Sequence
Alignment/Map format and SAMtools. Bioinformatics 25,
2078–2079.
43. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibul-
skis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel,
S., Daly, M., and DePristo, M.A. (2010). The Genome
Analysis Toolkit: a MapReduce framework for analyzing
next-generation DNA sequencing data. Genome Res. 20,
1297–1303.
44. Cingolani, P., Platts, A., Wang, L., Coon, M., Nguyen, T.,
Wang, L., Land, S.J., Lu, X., and Ruden, D.M. (2012). A
program for annotating and predicting the effects of single
nucleotide polymorphisms, SnpEff: SNPs in the genome of
Drosophila melanogaster strain w1118; iso-2; iso-3. Fly
(Austin) 6, 80–92.
45. Gao, X., Starmer, J., andMartin, E.R. (2008). Amultiple testing
correction method for genetic association studies using corre-
lated single nucleotide polymorphisms. Genet. Epidemiol. 32,
361–369.erican Journal of Human Genetics 92, 841–853, June 6, 2013 853
